Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution
Abstract
:1. Introduction
2. Materials and Methods
2.1. Protocol
2.2. Measurements
2.3. Statistics
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Meier, J.J.; Rosenstock, J.; Hincelin-Méry, A.; Roy-Duval, C.; Delfolie, A.; Coester, H.-V.; Menge, B.A.; Forst, T.; Kapitza, C. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care 2015, 38, 1263–1273. [Google Scholar] [CrossRef] [Green Version]
- Halawi, H.; Khemani, D.; Eckert, D.; O′Neill, J.; Kadouh, H.; Grothe, K.; Clark, M.M.; Burton, D.D.; Vella, A.; Acosta, A.; et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: A randomised, placebo-controlled pilot trial. Lancet Gastroenterol. Hepatol. 2017, 2, 890–899. [Google Scholar] [CrossRef]
- Hjerpsted, J.B.; Flint, A.; Brooks, A.; Axelsen, M.B.; Kvist, T.; Blundell, J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes. Metab. 2018, 20, 610–619. [Google Scholar] [CrossRef] [Green Version]
- Acosta, A.; Camilleri, M.; Burton, D.; O′Neill, J.; Eckert, D.; Carlson, P.; Zinsmeister, A.R. Exenatide in obesity with accelerated gastric emptying: A randomized, pharmacodynamics study. Physiol. Rep. 2015, 3, 12610. [Google Scholar] [CrossRef] [Green Version]
- Astrup, A.; Rossner, S.; Van Gaal, L.; Rissanen, A.; Niskanen, L.; Al Hakim, M.; Madsen, J.; Rasmussen, M.F.; Lean, M.E. Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. Lancet 2009, 374, 1606–1616. [Google Scholar] [CrossRef]
- Lorenz, M.; Pfeiffer, C.; Steinsträsser, A.; Becker, R.H.; Rütten, H.; Ruus, P.; Horowitz, M. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes—Relationship to postprandial glycemia. Regul. Pept. 2013, 185, 1–8. [Google Scholar] [CrossRef]
- Linnebjerg, H.; Park, S.; Kothare, P.A.; Trautmann, M.E.; Mace, K.; Fineman, M.; Wilding, I.; Nauck, M.; Horowitz, M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 2008, 151, 123–129. [Google Scholar] [CrossRef]
- Jones, K.L.; Rigda, R.S.; Buttfield, M.D.M.; Hatzinikolas, S.; Pham, H.T.; Marathe, C.S.; Wu, T.; Lange, K.; Trahair, L.G.; Rayner, C.K.; et al. Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes. Diabetes Obes. Metab. 2019, 21, 1158–1167. [Google Scholar] [CrossRef]
- Gentilella, R.; Pechtner, V.; Corcos, A.; Consoli, A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: Are they all the same? Diabetes Metab. Res. Rev. 2019, 35, 3070. [Google Scholar] [CrossRef] [Green Version]
- Jones, K.L.; Huynh, L.Q.; Hatzinikolas, S.; Rigda, R.S.; Phillips, L.K.; Pham, H.T.; Marathe, C.S.; Wu, T.; Malbert, C.H.; Stevens, J.E.; et al. Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations. Diabetes Obes. Metab. 2020, 22, 788–797. [Google Scholar] [CrossRef]
- Drucker, D.J. The biology of incretin hormones. Cell Metab. 2006, 3, 153–165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kastin, A.J.; Akerstrom, V.; Pan, W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J. Mol. Neurosci. 2002, 18, 7–14. [Google Scholar] [CrossRef]
- Chaudhri, O.; Small, C.; Bloom, S. Gastrointestinal hormones regulating appetite. Philos. Trans. R. Soc. B Boil. Sci. 2006, 361, 1187–1209. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paternoster, S.; Falasca, M. Dissecting the physiology and pathophysiology of glucagon-like peptide-1. Front. Endocrinol. 2018, 9, 584. [Google Scholar] [CrossRef] [Green Version]
- Hunter, K.; Hölscher, C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012, 13, 33. [Google Scholar] [CrossRef] [Green Version]
- Holst, J.J. Incretin hormones and the satiation signal. Int. J. Obes. 2013, 37, 1161–1168. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sturm, K.; Parker, B.; Wishart, J.; Feinle-Bisset, C.; Jones, K.L.; Chapman, I.; Horowitz, M. Energy intake and appetite are related to antral area in healthy young and older subjects. Am. J. Clin. Nutr. 2004, 80, 656–667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scheen, A.J. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 1996, 30, 359–371. [Google Scholar] [CrossRef] [PubMed]
- Borg, M.J.; Bound, M.; Grivell, J.; Sun, Z.; Jones, K.L.; Horowitz, M.; Rayner, C.K.; Wu, T. Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes. Diabetes, Obes. Metab. 2019, 21, 640–647. [Google Scholar] [CrossRef]
- Jones, K.L.; Horowitz, M.; Wishart, M.J.; Maddox, A.F.; Harding, P.E.; Chatterton, B.E. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J. Nucl. Med. 1995, 36, 2220–2228. [Google Scholar]
- Nair, N.S.; Brennan, I.M.; Little, T.J.; Gentilcore, D.; Hausken, T.; Jones, K.L.; Wishart, J.M.; Horowitz, M.; Feinle-Bisset, C. Reproducibility of energy intake, gastric emptying, blood glucose, plasma insulin and cholecystokinin responses in healthy young males. Br. J. Nutr. 2009, 101, 1094–1102. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Parker, B.A.; Sturm, K.; MacIntosh, C.G.; Feinle, C.; Horowitz, M.; Chapman, I.M. Relation between food intake and visual analogue scale ratings of appetite and other sensations in healthy older and young subjects. Eur. J. Clin. Nutr. 2004, 58, 212–218. [Google Scholar] [CrossRef] [Green Version]
- Aroda, V.R.; Rosenstock, J.; Wysham, C.; Unger, J.; Bellido, D.; González-Gálvez, G.; Takami, A.; Guo, H.; Niemoeller, E.; Souhami, E.; et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. Diabetes Care 2016, 39, 1972–1980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosenstock, J.; Aronson, R.; Grunberger, G.; Hanefeld, M.; Piatti, P.; Serusclat, P.; Cheng, X.; Zhou, T.; Niemoeller, E.; Souhami, E.; et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial. Diabetes Care 2016, 39, 2026–2035. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Turton, M.D.; O′Shea, D.; Gunn, I.; Beak, S.A.; Edwards, C.M.; Meeran, K.; Choi, S.J.; Taylor, G.M.; Heath, M.M.; Lambert, P.D.; et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379, 69–72. [Google Scholar] [CrossRef] [PubMed]
- Göke, R.; Larsen, P.J.; Mikkelsen, J.D.; Sheikh, S.P. Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 1995, 7, 2294–2300. [Google Scholar] [CrossRef] [PubMed]
- Alvarez, E.; Martínez, M.D.; Roncero, I.; Chowen, J.A.; Garcia-Cuartero, B.; Gispert, J.D.; Sanz, C.; Vazquez, P.; Maldonado, A.; De Cáceres, J.; et al. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 2005, 92, 798–806. [Google Scholar] [CrossRef]
- Van Bloemendaal, L.; Ijzerman, R.G.; Ten Kulve, J.S.; Barkhof, F.; Konrad, R.J.; Drent, M.L.; Veltman, D.J.; Diamant, M. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 2014, 63, 4186–4196. [Google Scholar] [CrossRef] [Green Version]
- Shah, M.; Vella, A. Effects of GLP-1 on appetite and weight. Rev. Endocr. Metab. Disord. 2014, 15, 181–187. [Google Scholar] [CrossRef]
- Lean, M.E.J.; Carraro, R.; Finer, N.; Hartvig, H.; Lindegaard, M.L.; Rössner, S.; Van Gaal, L.; Astrup, A. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int. J. Obes. 2014, 38, 689–697. [Google Scholar] [CrossRef] [Green Version]
- Horowitz, M.; Aroda, V.R.; Han, J.; Hardy, E.; Rayner, C.K. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences. Diabetes Obes. Metab. 2017, 19, 672–681. [Google Scholar] [CrossRef] [PubMed]
- Baggio, L.L.; Drucker, D.J. Glucagon-like peptide-1 receptors in the brain: Controlling food intake and body weight. J. Clin. Investig. 2014, 124, 4223–4226. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Geloneze, B.; De Lima-Júnior, J.C.; Velloso, L.A. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the brain-adipocyte axis. Drugs 2017, 77, 493–503. [Google Scholar] [CrossRef] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jalleh, R.; Pham, H.; Marathe, C.S.; Wu, T.; Buttfield, M.D.; Hatzinikolas, S.; Malbert, C.H.; Rigda, R.S.; Lange, K.; Trahair, L.G.; et al. Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. Nutrients 2020, 12, 1962. https://doi.org/10.3390/nu12071962
Jalleh R, Pham H, Marathe CS, Wu T, Buttfield MD, Hatzinikolas S, Malbert CH, Rigda RS, Lange K, Trahair LG, et al. Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. Nutrients. 2020; 12(7):1962. https://doi.org/10.3390/nu12071962
Chicago/Turabian StyleJalleh, Ryan, Hung Pham, Chinmay S. Marathe, Tongzhi Wu, Madeline D. Buttfield, Seva Hatzinikolas, Charles H. Malbert, Rachael S. Rigda, Kylie Lange, Laurence G. Trahair, and et al. 2020. "Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution" Nutrients 12, no. 7: 1962. https://doi.org/10.3390/nu12071962
APA StyleJalleh, R., Pham, H., Marathe, C. S., Wu, T., Buttfield, M. D., Hatzinikolas, S., Malbert, C. H., Rigda, R. S., Lange, K., Trahair, L. G., Feinle-Bisset, C., Rayner, C. K., Horowitz, M., & Jones, K. L. (2020). Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. Nutrients, 12(7), 1962. https://doi.org/10.3390/nu12071962